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Abstract: In this paper, the patho-physiological dynamics of  Human Immuno-deficiency Virus type 1( HIV-1) induced 1 
AIDS during Highly Active Anti Retroviral Therapy (HAART) is modeled by a system of non-linear deterministic 2 
differential equations. The physiologically relevant and clinically plausible equations depict the dynamics of uninfected 3 
CD4+ T cells (x1), HIV-1 infected CD4+ T cells (x2), HIV-1 virions in the blood plasma (x3), HIV-1 specific CD8+ T cells 4 
(x4), and the concentration of HAART drug molecules (x5). Criteria for the existence of therapeutic outcomes are 5 
presented. In particular, the necessary and sufficient conditions for the annihilation of HIV-1 virions, and HIV-1 infected 6 
helper T cells are clearly exhibited in terms of biological measureable model physiological parameters. Investigative 7 
computer simulations are presented elucidating the patho-physiodynamics of HIV-1 induced AIDS and various 8 
hypothetical patient parametric configurations. The mathematical analysis of the model equations and the computer 9 
simulations are performed with regard to HAART protocols with constant continuous intravenous and transdermal drug 10 
infusions.  11 
Keywords: HIV-1patho-physiodynamics, mathematical modeling, HAART therapy, AIDS cure criteria, 12 
Michaelis-Menten kinetics 13 
AMS Subject Classification: 93A30; 93D05; 93D20; 34A34; 92C42; 92C35 14 
1. Introduction 15 
 16 
Highly Active Anti-retroviral Therapy (HAART) is currently the most therapeutically efficacious treatment protocol for 17 
treating the Acquired Immunodeficiency Syndrome (AIDS). HIV-1 virions induce AIDS by orchestrating an irreversible 18 
destruction of the CD4+ T cells which then paralyze the immune system of the HIV-1 positive person. The major objectives of 19 
HAART therapy are the prolongation and improvement of the long-term life quality of patients; optimization of therapy such as 20 
to suppress the HIV-1 viral load to below 50 copies of HIV-1 RNA; reconstitution of the patients’ immune system such that the 21 
CD4+ T cells proliferate to carrying capacity; and minimization of drug toxicity. HAART treatment protocol consists of 22 
nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, anti-fungals 23 
/anti-bacterials and in future, integrase inhibitors. The reverse transcriptase inhibitors prevent reverse transcription of HIV-1 24 
specific DNA. The protease inhibitors are antagonistic to maturation and formation of new HIV-1 virions. The possible role of 25 
integrase inhibitors is to prevent the integration of HIV-1 viral DNA into the patients’ DNA[5,12] . 26 
In order to achieve the therapeutic goals of HAART, it is plausible to involve the techniques of mathematical modeling. 27 
Before the advent of HAART, the primary focus of the mathematical modelers is to quantitatively analyze the observed 28 
patho-physio dynamics of HIV-1 infection in the AIDS patients. These earlier research papers involve the pioneering work of 29 
Perelson et al. [13], Nowark et al [11],  and other contributors [16,17].  30 
A recent paper by Nani and Jin [ 10] provided some physiological criteria under which HIV-1 virions in an AIDS patient 31 
can be annihilated during HAART.  32 
Some of the earlier mathematical modeling publications focus on single-drug AIDS therapy using Zidovudine (INN) or 33 
azidothymidine (AZT) [9]. Then the advent of Active Retro-viral Therapy (ART) and the associated clinical limitation let to the 34 
development of HAART treatment protocols. In spite of the initial success of HAART, there are clinically measurable and 35 
observable shortcomings in the treatment of AIDS [4,].   In particular, HAART is not successful in about 40% of AIDS patients 36 
because of drug-induced toxicity and complications of treatment . HAART protocols have been clinically observed to have 37 
limited therapeutic efficacy due to biochemical/clinical drug resistance, short drug half-life, low bio-availability and blood 38 
plasma toxicities.  39 
Mathematical modeling provides a quantitative and rational approach to solve the therapeutic efficacy problems associated 40 
with HAART. In particular, the models focused on finding optimal therapeutic schedules, the roles of latent viral reservoirs as 41 
well as minimizing of toxic side effect[1,2,6,7,8,9,14,16,17]. 42 
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Optimal therapies that will minimize side effects have been investigated by many authors in [8, 9, 10, 11, 13, 14, 15, 16]. 43 
Zaric et al. in 1998 presented a model which was focused on the simulation of protease inhibitors and role of drug resistant 44 
HIV-1 virions [18]. Stengel in [14] presented a mathematical model of HIV-1 infection and HAART which demonstrated the 45 
efficacy of a mathematically optimal therapy. Caetano and Yoneyama in [2] constructed a HAART model which incorporated 46 
the roles of latently infected CD4+ T cells, and discussed how the reverse transcriptase and protease inhibitors affected HIV-1 47 
dynamics during HAART, using the LQR, Scheme. In a future paper, we will use Pontryagin’s Minimal Principle to construct 48 
admissible optimal therapies such as to minimize the toxicity of the drug but maximize the therapeutic efficacy of HAART.  49 
In this paper, an elaborate mathematical model will be constructed which will incorporate physiologically plausible effects 50 
such as Michaelis-Menten kinetics, role of HIV-1 latent viral reservoirs, continuous transdermal drug delivery, and the implicit 51 
lymphocyte proliferation induction by the CD4+ T cells. The activation and proliferation is accomplished by a paracrine and 52 
autocrine processes which are mediated by the cytokine interleukin-2, secreted by the CD4+ T cells.  Several authors 53 
investigated the consequences of structured long-term and short-term treatment interruptions during HAART [1, 2, 4, 8]. The 54 
current model will discuss these consequences by means of simulations.  55 
The current paper will be divided into seven sections. The first section gives the introduction into HAART therapy and 56 
provides the basis for current research. This is followed by presentation and discussion of the model parameters in Section 2. In 57 
Section 3 the mathematical model of HAART therapy will be constructed. Also the necessary and sufficient criteria for 58 
annihilation of HIV-1 virions during HAART will be presented in sections 4, 5, and 6. In Section 7, clinically plausible 59 
computer simulations will be exhibited. Section 5 will be the summary and discussion of the basic results of the paper.  60 
 61 
2. Parameters 62 
In this section, the physiological variable and parameters of the HAART model equations will be defined and explained. It 63 
must be emphasized that some of these parameters are biologically measurable or can be estimated using clinical techniques. In 64 
clinical experience, these parameters are different from patient to patient depending on their patho-physiological conditions.   65 
A list of model parameters, constants, and variables is shown as follows.  66 
x1: the number density of non-HIV-1-infected CD4+ helper T-lymphocytes per unit volume 67 
x2: the number density of HIV-1 infected CD4+ helper T-lymphocytes per unit volume 68 
x3: the number density of HIV-1 virions in the blood plasma per unit volume 69 
x4: the number density of HIV-1 specific CD8+ cytotoxic T-lymphocytes per unit volume 70 
x5: the concentration of drug molecules of the HAART treatment protocol 71 
S1:  rate of supply of un-infected CD4+ T4-lymphocytes  72 
S2:  rate of supply of latently infected CD4+ T4-lymphocytes 73 
S3: rate of supply of HIV-1 virions from macrophage, monocytes, microglial cells and other lymphoid tissue different from 74 
T4-lymphocytes 75 
S4:  rate of supply of CD8+  T8 lymphocytes from the thymus 76 
D:  rate of HAART drug infusion by transdermal delivery   77 
ai, bi: constant associated with activation of lymphocytes by cytokine interleukin-2 (IL-2) (i =1, 2, 3, 4) 78 
c:  rate of HAART drug degradation and excretion 79 
αi: constant associated with HIV-1 infection of CD4+ T4 helper cells (i =1, 2, 3) 80 
β1: the number of HIV-1 virions produced per day by replication and budding in CD4+ T4 helper cells  81 
β2: rate constant associated with replication and “budding” of HIV-1 in syncytia CD4+ T4 helper cells per day per microliter (µl) 82 
and released into the blood plasma  83 
β3: the number of HIV-1 virions produced per day by replication and “budding” in non-syncytia CD4+ T4 helper cells and 84 
released into the blood plasma 85 
ηi: constant depicting the rate of which HIV-1 virions incapacitate the CD8+ T8 cytotoxic cells (i =1, 2) 86 
(σ0, λ0): Michaelis-Menten nonlinear metabolic rate constants associated with HAART drug elimination 87 
(σi, λi): Michaelis-Menten nonlinear metabolic rate constants associated with HAART drug pharmacokinetics (i =2, 3) 88 
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ξi: cytotoxic coefficient where 0 ≤ ξi  ≤ 1 (i =  2, 3) 89 
qi: constant depicting competition between infected and un-infected CD4+ T4 helper cells (i =1, 2) 90 
ki: constant depicting degradation, loss of clonogenicity or  “death” (i =1, 2, 3, 4) 91 
k5: rate constant depicting linear drug elimination pharmacokinetics 92 
ei0: constant depicting death or degradation or removal by apoptosis (programmed cell death) (i =1, 2, 3, 4) 93 
Ki: constant associated with the killing rate of infected CD4+ T4 cells by CD8+  T8 cytotoxic lymphocytes (i =1, 2) 94 
All the parameters are positive  95 
 96 
3. Model Equations 97 
3.1. Description of the Model Equations  98 
The HIV-1 patho-physiological dynamics during HAART therapy can be modeled using the following system of 99 
non-linear ordinary differential equations: 
 
 100 
       
101 
     102 
 103 
 104 
 105 
 106 
 107 
 108 
 109 
                     for constant continuous input  110 
               for periodic input 111 
   (3.1) 
112 
The model includes the following clinical improvements: 113 
(i) The drug delivery uses transdermal, stealth-liposome encapsulated drug delivery, instead of the matrix tablet form because 114 
of improved therapeutic efficacy and reduced gastro-intestinal toxicity [6].  It is also assumed that elastic liposomes are 115 
formulated and selectively targeted such as to reduce toxicity to non-HIV-1-infected CD4+ T cells (x1) and CD8+ cytotoxic 116 
T cells (x4). 117 
(ii)  The HAART drug is such that each renal excretion and body clearance rate follows Michaelis-Menten kinetics. 118 
(iii) 111 ),( xbjjj jexxaxxg −= for  j=(1, 2, 4)  119 
This function depicts the process of lymphocyte activation which is mediated by x1 (CD 4+) T helper cells. These cells 120 
secrete a cytokine called interleukin-2. 121 
(iv) The periodic input function f(t)=  can be depicted by the following plot: 122 
 123 
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 125 
3.2. Boundedness and Invariance of Non-negativity of Solutions 126 
In this subsection theoretical conditions will be constructed under which solutions to the HAART mathematical model 127 
equations are well-posed, ultimately bounded, and exhibit invariance of non-negativity for all ),0[],[ 0 ∞=ℜ⊂∈ +Ttt . In this 128 
case, t0, and T are defined respectively as times at which HAART therapy begins and terminates.  129 
Theorem 3.1 Consider  130 
(i) 131 
 132 
Let 133 
 134 
(ii) 135 
 136 
Then there exists a T0>0 such that for T0 < t < ∞, all solutions to the HAART model equations (3.1) with initial values xi0 ∈ℜ5+ 137 
={xi∈ℜ | xi≥0, i=(1,2,3,4,5)} are ultimately bounded, dissipative, and will eventually enter the non-negatively invariant region 138 
Ω. In particular, the solutions are trapped in the region Ω for all +ℜ⊂> 0Tt  139 
Proof.  Using the result from Nani and Jin in [10], let   140 
       (3.2) 
141 
 
142 
Define 143 
             (3.3) 144 
And set  145 
     
320 δδδδ ++=          (3.4) 146 
The Kamke comparison theorem , cf. [10]  can be used to establish the following inequalities.   147 
 148 
 (3.5)
             
 149 
 150 
 151 
In particular, the following results can be obtained.  152 
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    153 
     (3.6) 154 
 155 
Thus, Ω is non-negatively invariant and the system is ultimately bounded, dissipative, with the bounds defined by the following 156 
equations.  157 
    158 
 159        (3.7) 159 
 160 
This completes the proof.          161 
4. The Rest Points and Computation of the Jacobian Matrices  162 
4.1 The list of rest points or physiological outcomes of HAART 163 
In this section, the possible patho-physiological outcomes from constant continuous transdermal HAART therapy are 164 
listed and analyzed.  165 
The physiological outcomes or the steady states during constant continuous transdermal HAART therapy occur when  166 
ix& = 0 for i=1,2,3,4,5 and f(t) ≡1 167 
In particular, the clinically relevant and physiological plausible therapeutic outcomes include the following: 168 
E1= [0, 0, 0, 0, x5] 169 
E2= [0, 0, 0, x4, x5] 170 
E3= [x1, 0, 0, x4, x5] 171 
E4= [x1, 0, 0, 0, x5] 172 
E5= [0, x2, x3, 0, x5] 173 
E6= [0, 0, x3, 0, x5] 174 
E7= [0, x2, 0, 0, x5] 175 
E8= [x1, x2, 0, 0, x5] 176 
E9= [x1, x2, 0, x4, x5] 177 
E10= [x1, x2, x3, x4, x5] 178 
There are some other steady states which are not listed because they are less clinically interesting.  179 
The clinically desirable steady states for a HIV-1 AIDS patient are E3 and E4. The steady state E10 depicts a person who is 180 
living with AIDS. In this case, the model exhibits persistence and the viral titer is not sufficient to annihilate the immune system. 181 
The steady states E1 and E2 represent scenarios of therapeutic failure because the CD4+ T cells (x1) are obliterated by the 182 
cytotoxicity of the HAART protocol. On the other hand, E5 represents the scenario in which HIV-1 virions (x3), HIV-1 infected 183 
CD4+ T cells (x2), and the HAART drug (x5) eliminate the uninfected CD4+ T cells (x1), and HIV-1 specific CD8+ T cells (x4). 184 
This is also an example of therapeutic failure for HAART protocol.  In E6 and E7, the uninfected CD4+ T cells are obliterated by 185 
the HAART protocol and consequently are not clinically desirable. The steady states E8 and E9 represent curious scenarios 186 
because the HIV-1 virions (x3) are eliminated from blood plasma but unfortunately the HIV-1 infected CD4+ cells (x2) remain 187 
and will constitute a reservoir from which the HIV-1 virions will burst and repopulate the blood plasma and re-infect other 188 
lymphoid organs.   189 
The clinically desirable steady states E3 and E4 as well as undesirable states E5 will be discussed in this section. The 190 
mathematical techniques used include the Hartman-Grobman theorem, non-linear dynamic systems theory, and the principles 191 
of linearized stability.  192 
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 193 
4.2 Computation of the Jacobian Matrices 194 
Using the Hartman-Grobman theorem, it is possible to investigate the physiological stability of HIV-1 AIDS disease 195 
dynamics associated with the model equations, in the neighborhood of the physiological outcomes (steady states).  196 
The Jacobian matrix of linearization near any physiological outcome is denoted symbolically by    197 
[ ] { } 5,4,3)(: 5555 =ℜ∈= ×× kMaEJ ijk
        (4.1) 198 
In particular, the aij entries are defined as follows: 199 
 200 
 201 
 202 
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 211 
             (4.2) 212 
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The Jacobian matrices for the steady states E3, E4, E5 are respectively listed as follows: 229 
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            (4.9) 240 
 241 
5.  Necessary Criteria for Various Therapeutic Outcomes of AIDS during HAART  242 
 243 
In this section, the necessary mathematical criteria for all therapeutic outcomes during HAART are computed and 244 
presented in the form of theorems.  245 
Theorem 5.1.  Suppose   246 
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The HAART therapeutic outcome E4[x1, 0, 0, 0, x5] exists and it is a local attractor.   249 
9 
 
 250 
 251 
 252 
Proof. Consider the model equations (3.1). Then criterion (5.1) is a necessary condition for the existence of   E4[x1, 0, 0, 0, x5]. 253 
Now the Jacobian matrix of linearization of the model equations in the neighborhood of E4[x1, 0, 0, 0, x5] is such that the 254 
eigenvalues are given by the following expressions. 255 
  
 256 
 257 
 258 
             (5.3) 259 
 260 
 261 
 262 
The eigenvalues have negative real parts when criterion (4.2) holds. Thus, two criteria (5.1) and (5.2) constitute the necessary 263 
conditions for the local existence of E4[x1, 0, 0, 0, x5]. In particular, the principles of linearized stability of dynamical systems 264 
can be used to imply that the rest point  E4[x1, 0, 0, 0, x5] is locally asymptotically stable and hence a local attractor.            265 
Clinical Implication 5.1. The criteria (5.1) and (5.2) guarantee a temporary cure for the AIDS patient. There will be a finite 266 
time interval during which the HIV-1 virions will be annihilated from the patient’s blood plasma. This will however be 267 
short-lived because the rest point E4[x1, 0, 0, 0, x5] may become unstable and the criteria for temporal cure are violated. It is 268 
possible for therapeutic criteria to be derived to maintain the patient to be permanently free of AIDS, which we shall discuss in 269 
Theorem 5.5. 270 
 271 
Theorem 5.2.  Suppose   272 
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(ii) Let ]}),0,,,0[{( 5325 xxxEJσ be the eigen-spectrum of 274 
 275 
 276 
 277 
            (5.5) 278 
 279 
such that  280 
  },{}3,2,1,0|{]}),0,,,0[{( 54322135325 λλλλλλσ ∪==+++= iaaaxxxEJ i   (5.6) 281 
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Then the rest point E5= [0, x2, x3, 0, x5] is locally asymptotically stable if  284 
32131 ,0,0 aaaaa >>>        (5.8) 285 
Proof. The physiological outcome or rest point E5 exists if criterion (5.4) is satisfied. The Hartmann-Grobman theorem as 286 
applied in  [10] in addition to  the principles of linearized stability can be applied to the model equations in the neighborhood of 287 
E5. The eigen-spectrum of the Jacobian matrix of the linearization is given by (5.6). Then the Routh-Hurwitz criterion [10] can 288 
be applied to (5.6) with definitions stated by (5.7). Thus, Theorem (5.2) follows immediately.   289 
Clinical Implication 5.2. This theorem depicts the conditions for one of the worst scenarios during AIDS therapy using 290 
continuous infusion HAART. If the conditions (5.4) and (5.8) hold, then the HAART therapy annihilated all the uninfected 291 
CD4+ T cells, and HIV-1 specific cytotoxic CD8+ T cells. Consequently, the immune system of the AIDS patient becomes 292 
incapacitated and the patient becomes the target of opportunistic infections. However, this situation may not last very long but 293 
could be fatal.  294 
 295 
Theorem 5.3. Suppose   296 
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The HAART therapeutic outcome E1[0, 0, 0, 0, x5] exists and it is a local attractor.   298 
Proof.  The proof follows directly from the definition of the rest point and inspection of the eigen-spectrum of the Jacobian 299 
matrix of linearization of the model equations in the neighborhood of E1.  300 
Clinical Implication 5.3. If the HAART protocol used for the AIDS patient is such that condition (5.9) is satisfied, then the 301 
patient experiences extreme immune system cytotoxicity in which the uninfected CD4+ T cells,  HIV-1 specific cytotoxic CD8+ 302 
T cells, HIV-1 virions, and HIV-1 infected CD4+ T cells are all decimated. This is not a therapeutically desirable clinical 303 
outcome, because the patient may become severely incapacitated. To avoid this scenario, the HAART therapy must 304 
implemented in such a way that criterion (5.9) is violated. 305 
 306 
 307 
 308 
 309 
 310 
 311 
 312 
 313 
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Let    be the eigen-spectrum for the Jacobian matrix ]},,0,0,[{( 5413 xxxEJ such that  314 
}5,4,3,2,1,0|)(|det|{]}),,0,0,[{( 35413 ==−= kIEJxxxEJ k λλσ  315 
 316 
Theorem 5.4.  Suppose  317 
 318 
 (i) 319 
            (5.10) 320 
 321 
 (ii) The eigenvalues of  ]},,0,0,[{( 5413 xxxEJ , represented by kkk iβαλ += , are such that the Re(λk) < 0. 322 
Then the rest point of E3 exists and is a local attractor. 323 
 324 
Proof. The condition (i) guarantees the local existence of E3. The principles of linearized stability can be used to show that 325 
condition (ii) ensures that E3 is locally asymptotically stable and hence is a local attractor.    326 
 Next, the interior rest point E10 is considered. This describes a situation in which the patient survives for a long time 327 
with AIDS. It is possible during HAART that, the HIV-1 virions cannot be annihilated but instead the system persists in a 328 
chronic configuration in which the blood plasma levels of the HIV-1 virions co-exist with the other clinically measurable 329 
parameters such as uninfected CD4+ T cells, the HIV-1 infected CD4+ T cells, HIV-1 specific CD8+ T cells, and HAART drug 330 
molecules. The criteria for existence of E10 are listed in the following theorem. 331 
Theorem 5.5. Let 332 
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 (i) 338 
 339 
 340 
 341 
 342 
             (5.11) 343 
 344 
 345 
 346 
 347 
 348 
 349 
 350 
 351 
 352 
 (ii)      353 
 354 
           (5.12) 355 
 356 
 357 
 358 
 359 
{ }
{ }
{ }
{ }
{ }



























+
+
+
+
+
=
++=
+=






+
+++=
=






+
+++=
++=
==
∈
∈
∈
∈
∈
∈
∈
−
∈
53
33
52
22
50
0
],[5
43222],[4
33322],[3
53
33
34113
],[
3
31
],[
1
52
5222
41212
],[
2
12131
],[
1
1],[
0
0
0
0
0
0
0
1
0
inf
inf
inf
sup
sup
sup
sup
}4,2,1{inf
x
x
x
x
x
L
kxxKL
xxxm
x
kxxL
xU
x
xx
xKkxqL
kxqxL
iwhereexxam
Ttt
Ttt
Ttt
Ttt
Ttt
Ttt
Ttt
xb
iiTtti
i
(
(
(
(
(
((
(((
(
((
(
(
((
((
((
(( (
λ
σ
λ
σ
λ
σ
η
ββ
λ
σξ
ηα
β
λ
σξ
α
















>≥
>
−+
≥
>
−+
≥
>
−−+
≥
>
−+
≥
0inflim
0inflim
0inflim
0inflim
0inflim
5
5
4
4044
4
3
3033
3
2
20122
2
1
1011
1
L
D
x
L
emS
x
L
emS
x
L
eUmS
x
L
emS
x








+
=
−=−
−=−
−
−
50
50
41444404
2
1111101
14
11
x
x
D
exxaxkeS
exaxkeS
xb
xb
λ
σ
]},,0,0,[{( 5413 xxxEJσ
12 
 
]0,0|,[ 515151 ≥≥=+ xxxxR xx
 360 
Then the system [x1, x2, x3, x4, x5] will persist and the HAART therapeutic outcome E10= ],,,,[ 54321 xxxxx ((((( exists. 361 
Proof. For a proof refer to  Nani and Jin[10].         362 
 363 
Clinical Implication 5.4. If uninfected CD4+ T cells, infected CD4+ T cells, the HIV-1 viral mRNA copies in the blood plasma, 364 
HIV-1 specific cytotoxic CD8+ T cells, and the HAART drug concentration are within certain thresholds, then the AIDS patient 365 
will live with AIDS. If any of the conditions listed in (5.11) are violated, the patient will experience unpredictable therapeutic 366 
outcomes including full-blown AIDS or spontaneous elimination of HIV-1 virions. 367 
 368 
6. Sufficient Criteria for Permanent Cure of AIDS during HAART 369 
In this section, the sufficient criteria for permanent annihilation of HIV-1 virions during HAART will be derived. The 370 
clinically desirable physiological outcomes are E4[x1, 0, 0, 0, x5] and E3= [x1, 0, 0,  x4,  x5]. It must be recalled that E4 371 
corresponds to the physiological outcome in which HIV-1 infected CD4+ T cells, the HIV-1 virions in the blood plasma and 372 
HIV-1 specific CD8+ T cells are eliminated in the blood plasma of the AIDS patient. The sufficient criteria for E4 will be 373 
discussed first.  374 
The rest point E4 will be analyzed for global asymptotical stability in the space         375 
The model equations (3.1) correspondingly reduce to the following: 376 
  377 
     378 
 379 
              (6.1) 380 
  381 
Consider the Liapunov functional: 382 
 383 
            (6.2)  384 
  385 
The derivative of V along the solution curves of the model equations yields the result: 386 
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But at a steady state, the following equations hold.  388 
    389 
            (6.4) 390 
  391 
 Define the following Lebesgue measurable, functions which are of bounded variation: 392 
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Let  396 
          397 
             (6.8) 398 
and 399 
 400 
             (6.9) 401 
 402 
and define define A={aij}∈M2X2(R) such that 403 
 404 
 405 
 406 
then 407 
             (6.10) 408 
 409 
Where XT  denotes the transpose of X and 
*
V  is negative definite if the eigenvalues of A have negative real parts or 410 
satisfy the conditions of a11 < 0 and det (A) > 0 [???]. 411 
 In particular, the [aij]2x2 are defined as follows: 412 
 413 
 414 
             (6.11) 415 
 416 
 417 
As the flow dynamics approaches the steady state E4[x1, 0, 0, 0, x5], the following conditions hold: 418 
 419 
             (6.12) 420 
 421 
where 422 
 423 
 424 
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In particular, 426 
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 429 
 430 
 The sufficient criteria for the global asymptotic stability of E4 are specified in the following theorem.  431 
Theorem 6.1 Let  432 
(i) Conditions (5.1) and (5.2) hold, 433 
(ii) Suppose 
1
2
1ˆ bx <  holds, 434 
then the rest point E4 is a global attractor such that the HIV-1 virions, HIV-1 infected CD4+ T cells, HIV-1 specific CD8+ T 435 
cells are annihilated during HAART. 436 
Proof. Condition (i) guarantees the local existence and local asymptotic stability of E4. If condition (ii) holds, then eigenvalues 437 
of the matrix A has negative real parts, and consequently, *V is negative definite. Hence, the theorem holds.        438 
Clinical Implication 6.1  439 
(i) The criterion 
1
2
1ˆ bx <  is a sufficient condition for annihilation of HIV-1 virions of the blood plasma of AIDS patient 440 
during HAART. 441 
(ii) The function )ˆ( 1xG is a measure of the rate at which the CD4+ T cells (x1) are activated by interleukin-2 (IL-2) in an 442 
autocrine process when the physiological flow during HAART tends to E4. It is possible to attach a biochemical 443 
measure to coefficient a1 and b1 of )ˆ( 1xG . This can be done as follows: 444 
 445 
 446 
 447 
 448 
 449 
Where 
1
1
b
Km = is approximately equal to the Michaelis-Menten constant of the CD4+ T cells activation reaction by 450 
interleukin-2, and Vmax represents the maximal velocity of the CD4+ T cells IL-2 activation reaction. 451 
(iii) Note that k1 is the rate of degradation and decay of the CD4+ T cells during AIDS. Thus the theorem implies that if 452 
the rate of degradation of CD4+ T cells is greater than the rate of IL-2 activation of T cells and if in addition, the 453 
number of the CD4+ T cells are such that  mKx 2ˆ1 < , then the patient will be cured of AIDS.  454 
 Next, the other clinical desirable rest point E3= [x1, 0, 0,  x4,  x5]  is analyzed. The aim is to find the sufficient criteria 455 
under which the HIV-1 virions in the blood plasma, the HIV-1 infected CD4+ T cells are annihilated but the HIV-1 specific 456 
CD8+ T cells will persist as memory T cells as well as the CD4+ T cells and some drug residues will remain in the AIDS patient. 457 
It is expected that the CD4+ T cells will eventually repopulate to their carrying capacity whereas the drug residues will 458 
ultimately dissipate.  The analysis will be similar to the preceding one for E4. 459 
 The restriction of the model equations to the space               leads to the following 460 
equations [nani and jin]. 461 
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 467 
                  (6.13) 468 
 469 
 470 
Consider the Liapnnov functional: 471 
      (6.14) 472 
 473 
 474 
The derivative of V along the solution curves of the model equations yields the result: 475 
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The functions G, F, L are continuous, Lebesgue measurable, and of bounded variations.  489 
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such that XT  denotes the transpose of X. Define C∈M3x3(R) such that  498 
 499 
 500   500 
 501             (6.19) 501 
 502 
Now  
503 
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 507 
Where the [cij]3x3 are defined as follows: 508 
                  (6.21) 
509 
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 511 
 512 
As the flow associated with the model equations approaches E3 = [ 1x , 0, 0, 4x , 5x ], the matrix entries [cij]3x3 have the 513 
following form: 514 
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               (6.22) 517 
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But it can be shown that  519 
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In particular, (cf. [nani and jin]) 525 
  526 
               (6.24) 527 
 528 
 529 










=
33232
1
132
1
232
1
22122
1
132
1
122
1
11
ccc
ccc
ccc
C
2
33323231313
3223
2
2221212
31132112
2
111
*
2
1
2
1
2
1
2
1
2
1
2
1
:
ucuucuuc
uucucuuc
uucuucucV
+++
+++
++=














−
−
−=
==
−=
==
=
−
−
−=
−
−
−−=
])()([:
0
0
]),(),([:
)])()(([:
55
55
533
3223
4422
3113
21
11
4141
412
11
11
11111
xx
xLxL
cc
cc
kcc
cc
c
xx
xxFxxF
cc
xx
xGxG
ckcc
)(
)],([
)]([
5533
4422
41412
111111
1
xLcc
kcc
xxFcc
xGckcc
x
′−→
−=
−→
′−−→
0)()(
)2()(
)1(),(
2
50
00
5
11111
414441
11
14
1
>
+
=′
−=′
−=
−
−
x
xL
bxexaxG
bxexaxxF
xb
xb
x
λ
λσ






><
==
<>
=
4
4
4
1
1
1
1
1
1
1
41
0
0
0
),(
b
b
b
x
xif
xif
xif
xxF
17 
 
Similarly, 530 
 531 
               (6.25) 532 
 533 
Using the specifications in (4.31), the matrix C has the form  534 
 535 
             (6.26) 536 
 537 
The matrix C is negative definite if the following criteria hold: 
538 
 539 
 540 
 541 
     (6.27) 542 
 543 
 544 
 545 
Theorem 6.2.  Suppose 
14
1
21
bb
x <=  546 
Then the physiological steady state E3=[ 1x , 0, 0, 4x , 5x ] is globally asymptotically stable and a global attractor.  547 
Proof. The condition (6.27) i. holds when           . But 0)( 1 >′ xG  when   121 bx < . Observe that if 411 bx = , then 548 
012 =c  and condition (6.27) ii. holds. Since  033 <c and 012 =c , the condition (4.37) also holds immediately. Hence the 549 
theorem follows.           550 
 551 
Clinical Implications 6.2.  552 
(i) Theorem 4.6 gives the sufficient theoretical criteria for the HIV-1 infected CD4+ T cells and HIV-1 virions in the blood 553 
plasma to be eradicated during HAART. This theorem also provides the conditions under which HIV-1 specific CD8+ T cells 554 
will persist as memory cells after the HAART therapy. 555 
(ii) It is possible to express the conditions of Theorem 4.6 in terms of clinically measurable biophysical parameters. By using 556 
Taylor expansions of             and           , the conditions   is approximately equivalent to the expression  557 
 558 
             (6.28) 559 
 560 
This can be interpreted to mean that HAART will cure the AIDS patient if the number density of uninfected CD4+ T cells is 561 
equal to the Michaelis-Menten constant of the IL-2 activation of the CD8+ T cells, which in turn has to be less than twice 562 
Michaelis-Menten constant of the IL-2 activation of the CD4+ T cells.  563 
 564 
Corollary 6.2. Suppose 
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565 
 Then the physiological steady state E3=[ 1x , 0, 0, 4x , 5x ] is a global attractor. 566 
Proof.  The conditions (4.37) i, ii, iii hold if the theorem hypothesis is satisfied. This makes the matrix C in (4.27) negative 567 
definite. Consequently, the steady state becomes global attractor.           568 
 569 
It is possible to combine Theorem 4.6 and Corollary 4.6 to obtain the combines criteria: 570 






><
==
<>
=′
1
1
1
2
1
2
1
2
1
1
0
0
0
)(
b
b
b
xif
xif
xif
xG
0])([0
00
0
0
det.
0)(0det.
00det.
2
124
1
221133
33
22122
1
122
1
11
3
2
124
1
2211
22122
1
122
1
11
2
11111
<−<=
>−>=
<<=
ccccor
c
cc
cc
Ciii
cccor
cc
cc
Cii
corcCi










=
33
22122
1
122
1
11
00
0
0
c
cc
cc
C
0)( 11 >′> xGk
11xbe
− 14xbe
−
14
1
21
bb
x <=
++ <= 481 2
CD
m
CD
m KKx
18 
 
   
14
1
21
bb
x ≤=
 
571 
 572 
 573 
7. Simulation Results 574 
        In this section investigative  computer simulations will be presented and  discussed . These simulations  are 575 
performed using clinically plausible  hypothetical patient patho-physiological parametric configurations. The numerical 576 
estimates used are variations of estimates published in the references: [  2,11,13,15].  Some techniques for estimating HIV-I 577 
dynamical parameters have been described by Ciupe et al. [2].   It must be emphasized that every AIDS patient has a unique 578 
situation and therefore these simulation results are hypothetical scenarios and depict non-equilibrium  disease configurations 579 
but do not depict the equilibrium AIDS configurations represented by the necessary and sufficient theorems  discussed in 580 
section 6. However the investigative computer simulations elucidate several dynamical aspects of HIV-1 AIDS dynamics 581 
which  are based  on the respective parametric configurations .  In a future publication the equilibrium parametric configuration 582 
simulations will be presented. The x-axis of the simulation graphs is calibrated in months. 583 
7.1 Simulation results for hypothetical AIDS patient #1  584 
The AIDS patho-physiological parametric configuration of hypothetical patient #1 is denoted by P1 and exhibited in 585 
Table 1. A brief inspection of the data reveals explicitly that it is a non-equilibrium scenario. The simulation results show that 586 
the HAART protocol impairs HIV-1 dynamics in this patient leading to eradication of plasma HIV-1 viremia. The simulation 587 
results for patient #1 are exhibited in Figure 1. It can observed that the HIV-1 infected CD4+ T cells are  eradicated in this 588 
patient with the use of anti-AIDS pharmaco-therapeutic drug protocols.  In addition, patient #1 experiences HAART- induced 589 
immune system reconstitution as the uninfected CD4+ T cells  and HIV-1 specific CD8+ T cells repopulate.   590 
 591 
Table 1 Parametric Configuration Ρ1 592 
TABLE I. Hypothetical AIDS Patient Parametric Configuration Ρ1    
S1 = 800 /day/µl 
a1 = 0.15 /day/cell/µl 
b1 = 0.019 /cell/µl 
α1 = 
0.5/day/virion/µl 
k1 = 0.0005/day/µl 
q1 = 
0.00045/day/µl/cell 
e10 =  
0.0025 cells/day/µl 
x10 = 500 cells/µl 
S2 = 800 /day/µl 
a2 = 0.03 /day/cell/µl 
b2 = 0.004/cell/µl 
α2= 0.5/day/virion/µl 
k2 = 0.005/day/µl 
q2 = 0.00001/day/µl/cell 
β1 = 1.05 
virons/CD4+/day 
K1 = 0.0001/day/µl 
e20 = 0.005 cells/day/µl 
ξ2 = 0.85 
x20 = 400 cells/µl 
 
S3 = 10 /day/µl 
β2 = 0.0015 
      virons/CD4+/day/µl 
β3 = 1.05 
virons/CD4+/day 
α3 = 0.027 /day/virion/µl 
k3 = 0.0001/day/µl 
e30 = 0.0001 /day 
η1 = 0.25 
ξ3 = 0.001 
x30 = 500 cells/µl 
S4 = 10 /day/µl 
a4 = 0.35 /day/cell/µl 
b4 = 0.01/cell/µl 
K2 = 0.0024 /day/µl 
k4 = 0.08/day/µl 
e40 = 0.0002 
cells/day/µl 
η2 = 0.45 
x40 = 730 cells/µl 
D = 5000 units 
σ0 = 0.5 mg/day 
σ2 = 30 mg/day 
σ3 = 5 mg/day 
λ0 = 5 mg/L 
λ2 = 15 mg/L 
λ3 = 0.025 mg/L 
x50 = 1500 cells/µl 
k5 = 0.0 /day 
constant infusion 
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                                       Figure 1 Simulation results using parametric configuration Ρ1 
 
7.2 Simulation results for hypothetical AIDS patient #2 
 The hypothetical AIDS patient #2 is assigned the patho-physiological parameter configuration P2  as presented in Table 2. 
As in the previous simulation, the configuration P2 does not depict an equilibrium configuration. The simulation results are 
exhibited in Figure 2. It can be observed that the this patient does  have a clinically favorable prognosis under HAART 
treatment protocol.  The AIDS patho - physiodynamics during the given HAART protocol  is similar to that for patient #1, as 
the patient #2 also undergoes immune system reconstitution in which the CD4+ T cells repopulate. On the other hand, the 
proliferative  activity of the HIV-1 specific CD8+ T cells appears to be down-regulated..  
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Table 2 Parametric Configuration Ρ2 
 
      
TABLE 2. Hypothetical AIDS Patient Parametric Configuration Ρ2   
S1 = 800 /day/µl 
a1 = 0.15 /day/cell/µl 
b1 = 0.005 /cell/µl 
α1 = 0.5/day/virion/µl 
k1 = 0.0005/day/µl 
q1 = 
0.00045/day/µl/cell 
e10 = 0.0025 
cells/day/µl 
x10 = 500 cells/µl 
S2 = 800 /day/µl 
a2 = 0.03 /day/cell/µl 
b2 = 0.004/cell/µl 
α2= 0.5/day/virion/µl 
k2 = 0.005/day/µl 
q2 = 
0.00001/day/µl/cell 
β1 = 1.05 
virons/CD4+/day 
K1 = 0.0001/day/µl 
e20 = 0.005 cells/day/µl 
ξ2 = 0.85 
x20 = 400 cells/µl 
 
S3 = 10 /day/µl 
β2 = 0.0015    
       virions/CD4+/day/µl 
β3 = 1.05 
virons/CD4+/day 
α3 = 0.027/day/virion/µl 
k3 = 0.0001/day/µl 
e30 = 0.0001 /day 
η1 = 0.25 
ξ3 = 0.001 
x30 = 500 cells/µl 
S4 = 10 /day/µl 
a4 = 0.35 /day/cell/µl 
b4 = 0.01/cell/µl 
K2 = 0.0024 /day/µl 
k4 = 0.08/day/µl 
e40 = 0.0002 
cells/day/µl 
η2 = 0.45 
x40 = 730 cells/µl 
D = 5000 units 
σ0 = 0.5 mg/day 
σ2 = 30 mg/day 
σ3 = 5 mg/day 
λ0 = 5 mg/L 
λ2 = 15 mg/L 
λ3 = 0.025 mg/L 
x50 = 1500 cells/µl 
k5 = 0.0 /day 
constant infusion 
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                        Figure 2 Simulation results using parametric configuration Ρ2 
  
 
       7.3 Simulation results for hypothetical AIDS patient #3  
For this scenario, the patho-physiological parametric configuration of hypothetical patient #3 is as shown in Table 3. It 
must be noted that HIV-1 AIDS dynamics during HAART treatment protocol in this patient is exacerbated by contributions 
from latent reservoirs in contrast to the other hypothetical patients. The results of the simulation are shown in Figure 3. This is 
a non-equilibrium AIDS configuration simulation as it is evident parametric configuration and by the simulation time profile. 
The simulation results show that during the given HAART protocol, the hypothetical AIDS patient #3 experiences annihilation 
of uninfected CD4+ T cells and  the HIV-1 specific CD8+ T cells . Consequently, immune system paralysis occurs as a 
consequence of the low CD4+ T cell number density, e leading to an exponential increase of the blood plasma HIV-1 viremia. 
This simulation represents an unfavorable AIDS outcome during HAART.  
Table 3 Parametric Configuration Ρ3 
TABLE 3. Hypothetical AIDS Patient Parametric Configuration Ρ3   
S1 = 800 /day/µl 
a1 = 0.15 /day/cell/µl 
b1 = 0.003 /cell/µl 
α1 = 0.5/day/virion/µl 
k1 = 0.0005/day/µl 
q1 = 
0.00045/day/µl/cell 
e10 = 0.0025 
cells/day/µl 
x10 = 250 cells/µl 
S2 = 800 /day/µl 
a2 = 0.03 /day/cell/µl 
b2 = 0.004/cell/µl 
α2= 0.5/day/virion/µl 
k2 = 0.005/day/µl 
q2 = 
0.00001/day/µl/cell 
β1 = 1.05 
virons/CD4+/day 
K1 = 0.0001/day/µl 
e20 = 0.005 cells/day/µl 
ξ2 = 0.85 
x20 = 400 cells/µl 
 
S3 = 10 /day/µl 
β2 = 0.0015    
       virions/CD4+/day/µl 
β3 = 1.05 
virons/CD4+/day 
α3 = 0.027/day/virion/µl 
k3 = 0.0001/day/µl 
e30 = 0.0001 /day 
η1 = 0.25 
ξ3 = 0.001 
x30 = 500 cells/µl 
S4 = 10 /day/µl 
a4 = 0.35 /day/cell/µl 
b4 = 0.002/cell/µl 
K2 = 0.095 /day/µl 
k4 = 0.08/day/µl 
e40 = 0.0002 
cells/day/µl 
η2 = 0.45 
x40 = 730 cells/µl 
D = 5000 units 
σ0 = 1.0 mg/day 
σ2 = 30 mg/day 
σ3 = 5 mg/day 
λ0 = 5 mg/L 
λ2 = 15 mg/L 
λ3 = 0.025 mg/L 
x50 = 3000 cells/µl 
k5 = 0.0 /day 
Constant Infusion 
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                              Figure 3 Simulation results using parametric configuration Ρ3 
 
 
 
 
 
8. Summary, Discussion and Future Work 
The current paper is elaborate and quantitative attempt to construct medically applicable mathematic models and derive 
criteria for efficacious HAART protocol for an AIDS patient. The mathematical equations presented in Section 3 are a 
generalization of the models by Wodarz and Nowak [16], Perelson  et al[13], Tang et al. [15],  and many other authors by 
incorporating more clinically relevant parameters of HIV-1 patho-physiodynamics. In particular, interleukim-2 activation of 
both CD4+ T cells and CD8+ T cells are implicitly incorporated into the model. In this paper, it has been demonstrated that the 
parameters (a1, b1) and (a4, b4) play a significant role in determining the efficacious outcomes of HAART. Clearly, the 
clinically desirable outcomes are the rest points E4 and E3. The criteria for the existence of E4 and E3 are listed respectively in 
Theorem 5.1, and Theorem 5.4. These theorems give the conditions under which both E4 and E3 can be temporarily or 
transiently attained. The criteria for E4 and E3 to become global attractors are listed Theorem 6.1 and Theorem 6.2. These 
theorems, expressed in terms of simple clinically attainable and measurable parameters, give the sufficient conditions for the 
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cure of AIDS. It will be emphasized that there exist other therapeutic criteria but these are intractable and extremely arduous to 
achieve in a clinical setting.  
One essential feature of this research is that the HAART protocol is implemented by using the constant continuous 
intravenous infusion or constant continuous transdermal infusion of the drug. As such, the criteria derived in this paper are 
applies to these settings. The mathematical model for intermittent caplet or matrix tablet per oral drug administration can be 
derived using the non-autonomous version of the model equations involving the drug input function f(t) discussed by Nani and 
Jin in [10].  
The scenarios for clinical failure during HAART due to extreme drug toxicity are represented by the rest points E1 and 
E5.The criteria for these therapeutic outcomes are described by Theorem 5.3 and Theorem 5.2, respectively.  
The future work will involve the construction of mathematical models which will describe an AIDS therapy using HAART 
in addition to ACI (Active Cellular Immunotherapy) involving interleukim-2. Also, in the future, the mathematical model for 
HAART will include the roles of mutations such as the delta32 CCR5 on therapeutic outcomes.      
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